FDA launches safety review of mifepristone abortion pill

The U.S. Food and Drug Administration has opened a retrospective safety study of mifepristone, the medication used for medical abortions. The review will examine hundreds of thousands of real‑world cases and is expected to take about six months, with interim findings due in July. Officials say the study could lead to tighter federal rules on telehealth prescribing and mail‑order distribution, which were expanded under the Biden administration and have become a focal point for Republican lawmakers. The review follows legal challenges from the state of Louisiana that seek to reinstate in‑person dispensing requirements, as well as a court order for the FDA to report on its safety assessment by October. While a ban is considered unlikely, the outcome may affect how the drug is prescribed, who can prescribe it, and whether remote access continues.

The investigation comes amid a broader political debate over abortion access, with the Trump administration urging a faster review and pro‑life groups pressing for stricter oversight. The FDA emphasizes that the study is part of its routine post‑market surveillance, but the timing and potential regulatory changes have drawn significant attention ahead of upcoming elections.